In addition, the difference between the lowest plasma glucose levels before and after the start of glinide was also calculated
In vivo, however, GLP-1GIPlanifibranor outperforms GLP-1RGIPR co-agonism and semaglutide, further decreasing body weight, food intake and hyperglycaemia in obese and insulin-resistant mice through synergistic incretin and PPAR action
For each article, the following data were extracted by 2 independent reviewers: the quality of the control groups and the homogeneity of the confounding factors between the groups, the level of expression (mRNA, protein) and the direction and amplitude of variation of the candidate biomarker, the adjustments of the results according to the subtypes of endometriosis, the phase of the menstrual cycle, the treatments and the symptoms and the ROC curve analysis to highlight diagnostic accuracy if available
GLP-1 receptor agonists (GLP-1 RAs) are primarily used to treat obesity and type 2 diabetes
doi: 10.1016/j.freeradbiomed.2009.01.004